IntroductIon
Tuberculosis is a common infectious disease worldwide. Tuberculosis is caused by a pathogenic bacterium, namely Mycobacterium tuberculosis. This infection can result in chronic unexplained clinical problems of chronic cough and weight loss. The pathogen, M. tuberculosis, can cause a long-term clinical problem. The infected patients might be wasted and might finally die. [1] As an important public health problem, the good management of tuberculosis by medical therapy is needed. At present, the gold standard for the treatment of tuberculosis is antituberculosis drug treatment. [1, 2] Tuberculosis is common among the groups of people with poor sanitation and low immunity. Of several groups of people, the patients with human immunodeficiency virus (HIV) infection become an important group affecting by tuberculosis. The tuberculosis is accepted as an important concomitant infection from HIV-infected patients. Tuberculosis is also an important leading cause of death for the HIV-infected patients. [3, 4] Due to the immune defect in HIV-infected patients, a patient can easily get concomitant infection including tuberculosis. At present, there is still no curative treatment for HIV infection. Nevertheless, the standard effective management of HIV infection is the antiretroviral therapy. At present, several antiretroviral drugs are available and proven effective in control of HIV infection. [5] It is suggested that all HIV-infected patients should receive antiretroviral drug treatment for stabilizing of the disease. [5] It is proven that the combined therapy by both antituberculosis and antiretroviral drugs is useful in the management of coinfection.
Since there is a change that there might be a concurrence between tuberculosis and HIV infections, it is required to search for the possible co-occurrence. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] If there is a proof of coinfection, treatment for both medical problems is needed. Routinely, the use of both antituberculosis drug and antiretroviral drug treatments is required. [16] Since the combination therapy means the use of several drugs, the chance of drug-drug interaction becomes an important consideration in clinical pharmacology. For HIV-infected patients with tuberculosis, the adverse effect due to the use of both antituberculosis drug and antiretroviral drug treatments is possible. [16] It is no doubt that there might be an interaction. It is recommended for good drug section and closed monitoring for any patient requiring concomitant antituberculosis drug and antiretroviral drug therapies. However, there is no systematic analysis on the severity degree of possible interaction. Here, the authors performed a bioinformatics analysis for analyzing the possible interactions among antituberculosis and antiretroviral drugs.
Methods
Here, the authors performed an informatics study. As an informatics study, which does not deal with any human or animal subjects and clinical specimens, there is no requirement for written informed consent or ethical approval. The main of the present work is to clarify the interactions between antituberculosis drug and antiretroviral drug. The studied antituberculosis drugs include rifampicin, isoniazid, pyrazinamide, and ethambutol. The studied antiretroviral drugs include nevirapine, efavirenz, lamivudine, tenofovir, zidovudine, rilpivirine, stavudine, atazanavir, lopinavir, ritonavir, abacavir, darunavir, and raltegravir [ Table 1 ]. All drugs are separately analyzed in the present study. No combination of drugs is analyzed. This is not a study on human or animal subjects and required no ethical approval.
The standard drug-drug interaction analysis was performed. The possible interaction between antituberculosis drug and antiretroviral drug was accessed accompanied with prediction of degree of severity of possible interaction. The work is based on standard bioinformatics tool, drug interaction checker, which is freely available online at https://www.webmd.com/ interaction-checker. The tool is an informatics tool using computational approach for analysis, and the technique is purely in silico and not involves any patient, animal, or clinical specimen. The tool can help predict and clarify interaction between two drugs. The predicted results are (a) whether there is any interaction or not and (b) in case that there is an interaction, the interaction occurs at which degree (degrees of possible drug-drug interaction include 1 = minor, 2 = monitor closely, 3 = serious, and 4 = don't use together. N/A means no predicted interaction).
results
The predicted drug-drug interaction between antituberculosis drug and antiretroviral drug is shown in Table 2 . There are many possible drug-drug interactions, and there are also various degrees of identified interactions. For all studied antituberculosis drug, there is no predicted drug-drug interaction for ethambutol. Globally, HIV infection is still an important public health threaten. Several millions of HIV-seropositive patients reside around the world. HIV is still an exact public health burden presently. The management of HIV infection becomes important public health strategies for public health management in any country. The use of antiretroviral drug therapy is a basic important clinical practice. In addition, the management of concurrent medical disorder among HIV-infected cases is needed. Due to impaired immune status, there are several possible concurrent medical problems among HIV-infected patients. [3] A possible important concurrent problem is tuberculosis infection. The tuberculosis is an important comorbidity among HIV-infected patients, and there is a requirement for good clinical management. [3, 4] The use of both antituberculosis and antiretroviral drugs is the basic clinical management of the patients with both HIV infection and tuberculosis. The advantage of disease control by the simultaneous therapy is confirmed. [3, 4] However, an important clinical issue that is widely discussed is the possible unwanted clinical problem due to the combining usage of both antituberculosis drug and antiretroviral drugs. The great concern is usually on the possible drug-drug interaction between antituberculosis drug and antiretroviral drug. In fact, the adverse effect of drugs usually increases when there are many drugs used at the same time for the management of the same patient. Conceptually, polydrug use is not recommended if there is no exact requirement. For the case of a patient with both HIV infection and tuberculosis, there is a need for the use of several drugs. Manosuthi et al. noted that adverse reactions to either antituberculous or antiretroviral drugs, as well as immune reconstitution inflammatory syndrome, are common in patients receiving integrated therapy by both antituberculosis and antiretroviral drugs. Manosuthi et al. suggested that "Early recognition and appropriate management of these consequences can reinforce the successful integrated therapy in HIV-infected patients with tuberculosis. [17] " The provision of enhanced monitoring of drug-drug interactions and adverse side effects are important concepts in the present integrated therapy by both antituberculosis and antiretroviral drugs for the patients with both infections. [18] In the present study, the interaction can be seen in many drugs, in both antituberculosis drug and antiretroviral drug groups. For example, many interactions are predicted for rifampicin. In fact, drug-drug interaction is well known in rifampicin use. Semvua et al. noted that "Rifampicin is a very potent enzyme inducer, which can result in subtherapeutic antiretroviral drug concentrations. [19] " In addition, the hepatotoxicity due to the combination of rifampicin with other drugs is the common concern in clinical pharmacology. In a recent report from Nigeria, the rifampicin-related hepatotoxicity is strongly related with concomitant antiretroviral drug use. [20] On the other hand, the drug-drug interaction induced by rifampicin also results in the requirement for antiretroviral drug dosage adjustment in efavirenz use. [21] The result in the present informatics study is also concordant with the previous observation among the trials in real patients. [21] According to a recent study, Naidoo et al. found that individual drug switched for toxicity occurred at incidence rate 2.1 per 100 person-years in HIV-tuberculosis coinfection receiving integrated therapy. [22] Regarding antiretroviral drugs, several drugs can cause drug-drug interactions according to the present prediction. In a recent study from Malawi, the patients with concurrent HIV and tuberculosis receiving different antiretroviral drugs did not show a significant different in adverse effect rate, but there was an observation on a nonstatistical different rate among different drugs. [23] Based on the present study, the possible drug-drug interactions can be demonstrated. Several drugs might involve in possible interactions. Furthermore, some interactions are considered serious. Nevertheless, some drugs are considered safe. The selection of the proper concomitant therapy with antituberculosis and antiretroviral drugs is necessary. A more complex situation can be expected in case that there are other additional medical problems in the patients such as hepatitis virus infection. In case of concurrent HIV and tuberculosis infection plus hepatitis virus infection, additional drugs for the management of viral hepatitis might cause additional drugdrug interaction complicating the integrated therapy. Further researches on the more complex situations of combined HIV, tuberculosis, and other medical problems are recommended.
conclusIon
There is a possibility for drug-drug interaction between antituberculosis drug and antiretroviral drug. The interaction might occur at various severity degrees. The monitoring of concomitant use of drugs in each specific HIV-infected individual is necessary, and the specific concerns should be given in many cases receiving the combination with possible high severe drug-drug interaction. Several drugdrug interactions are predicted for rifampicin and isoniazid. The most severe interactions are predicted for rifampicin. Regarding antiretroviral drugs, lamivudine, tenofovir, zidovudine, rilpivirine, abacavir, stavudine, nevirapine, and stavudine have not predicted interaction.
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